BCL2 and non-small cell lung carcinoma: Based on previous reports, we characterized maritoclax alone and in combination with the BCL-2/xL-specific inhibitor navitoclax in a panel of nine NSCLC cell lines with mutation profiles proportional to that seen in lung cancer patients.